Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and disabling side effects of cancer treatment. Caused by neurotoxic chemotherapy agents -- particularly platinum compounds (oxaliplatin, cisplatin), taxanes (paclitaxel, docetaxel), and vinca alkaloids -- CIPN produces distal sensory loss, pain (burning, tingling, electric-shock sensations), and in severe cases motor weakness. The sensory loss in the feet directly impairs proprioception and balance, creating a fall risk that persists months to years after chemotherapy ends.
How CIPN Affects Walking
- Plantar sensory loss: The feet lose the ability to detect ground texture, temperature, and pressure variations. The person cannot feel whether they are on stable ground or not. Proprioception -- the detection of foot and ankle position -- is severely impaired. This is the primary walking limitation in CIPN
- Balance impairment: The sensory input from the feet (somatosensory system) normally contributes approximately 70% of balance information during standing. When this input is eliminated by CIPN, balance in normal standing conditions deteriorates markedly, and in low-light conditions (vestibular and visual backup also less available) the fall risk is very high
- Pain with walking: The burning, electric pain of CIPN is often provoked by foot contact during walking, reducing walking tolerance
- Motor weakness (severe CIPN): In severe CIPN from vinca alkaloids, motor fibre involvement causes distal weakness and foot drop
Cane as Sensory Substitution in CIPN
The cane in CIPN serves primarily as sensory substitution -- not load transfer:
- Ground contact through the cane tip provides a somatosensory input that bypasses the numb feet entirely. The signal enters through the hand and arm rather than the feet
- This allows the person to detect ground surface changes (edge of a step, transition from carpet to tile, uneven ground) via the cane before the foot contacts the surface
- The cane also widens the base of support, directly compensating for the balance deficit
CIPN Recovery and Cane Duration
CIPN from platinum compounds often improves partially over 6-24 months after chemotherapy ends, but complete recovery is not guaranteed. The walking aid need should be reassessed at 6-monthly intervals as sensory function may partially recover. Many patients have some residual neuropathy indefinitely.
CIPN Severity and Cane Indication
| CIPN Grade | Sensory/Motor Features | Cane Role |
|---|---|---|
| Grade 1 (mild) | Tingling/numbness; no functional impact | Cane not usually required; monitor |
| Grade 2 (moderate) | Sensory loss limiting daily activities; balance impaired | Cane for outdoor use, uneven terrain, low-light environments |
| Grade 3 (severe) | Significant sensory loss; fall risk; possible foot drop | Cane essential; AFO if foot drop present; daily use |
| Grade 4 (life-threatening) | Disability; cannot walk safely alone | Forearm crutches or rollator; cane insufficient |
Related: Walking Cane After Chemotherapy and CIPN. Explore DaiWalk walking canes.
